OncoMatch/Clinical Trials/NCT06676449
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Is NCT06676449 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Immunotherapy and chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens for esophageal carcinoma.
Treatment: Immunotherapy · chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens — The goal of this clinical trial is to learn if immunotherapy in combination with tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) and chemotherapy works to treat locally advanced esophageal squamous cell cancer in adults. Researchers will compare immunotherapy in combination with TDLN-sparing RT and chemotherapy to TDLN-sparing RT and chemotherapy to see if immunotherapy works more effectively when using TDLN-sparing RT to treat locally advanced esophageal squamous cell cancer Participants will: TDLN-sparing RT for esophageal cancer 50.4Gy/28Fx Paclitaxel plus cisplatin every 3 weeks for 4 cycles PD-1 inhibitors or observation every 3 weeks for 1 year
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T2-4N0M0, TXN+M0, TXNXM1 (ONLY FOR SUPRACLAVICULAR LYMPH NODES METASTASIS) (8th UICC-TNM classification)
Clinical stages T2-4N0M0 or TxN+M0 or TxNxM1 (Only for supraclavicular lymph nodes metastasis) based on the 8th UICC-TNM classification
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Absolute neutrophil counts (ANC) ≥1.5×10^9⁄L; Hemoglobin (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×10^9⁄L
Kidney function
Creatinine ≤1.5 ULN
Liver function
Total bilirubin ≤1.5 upper limit of normal (ULN); AST ≤2.5 ULN; ALT ≤2.5 ULN
Adequate organ functions Absolute neutrophil counts (ANC) ≥1.5×10^9⁄L; Hemoglobin (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×10^9⁄L; Total bilirubin ≤1.5 upper limit of normal (ULN); Aspartate transaminase (AST) ≤2.5 ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine ≤1.5 ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06676449 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage T2-4N0M0 or TXN+M0 or TXNXM1 (ONLY FOR SUPRACLAVICULAR LYMPH NODES METASTASIS) is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages